{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:43:52Z","timestamp":1792122232685,"version":"4.4.0"},"reference-count":236,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Multiple Myeloma (MM) is the third most common hematological malignancy worldwide. Despite advancements in available therapies, MM remains incurable for most patients, mainly due to the early relapse and eventual resistance to therapy, underlining the need for novel drugs. Among these, multi-specific antibodies (MsAbs) have emerged as promising agents. Multi-specific immune cell-engaging antibodies, such as bi-specific, and tri-specific are designed to recognize two or more antigens on the same or distinct cells. These antibodies could promote cancer cell clearance by engaging both myeloma cells and cytotoxic immune cells such as T and Natural killer (NK) cells and macrophages (M). Currently, four bi-specific T cell engagers (teclistamab, elranatamab, talquetamab and linvoseltamab) are approved for refractory or relapsed MM patients (RRMM). While these therapies have demonstrated promising results in achieving deep remissions in RRMM, primary resistance occurs in about one-third of patients. Initially, immune engager research focused only on T cells due to their crucial anti-cancer role, but more recently, interest has expanded to NK cells and M for broader therapeutic potential. To date, several NK and M engaging MsAbs with mainly bi-specific and tri-specific formats are in clinical or preclinical evaluation for improving MM patients\u2019 response and reduce treatment related toxicity. This review discusses the recent advancement in T, NK and M engaging MsAbs in treating MM, including immunological background, mechanisms of action, relevant clinical and preclinical advancements and challenges. Moreover, we discuss the advantages and drawbacks of the different immune cell engagers. Furthermore, we review recent studies investigating the clinical and molecular determinants of resistance along with the latest predictive or prognostic biomarkers of response to MsAbs. Finally, we explore novel strategies to enhance MsAbs efficacy and reduce their toxicity, providing long-term disease control and improving survival in MM patients.<\/jats:p>","DOI":"10.3389\/fimmu.2026.1822508","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:14:23Z","timestamp":1783412063000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging precision medicine in multiple myeloma: clinical and preclinical landscape of T cell, natural killer cell, and macrophages engaging multi-specific antibodies"],"prefix":"10.3389","volume":"17","author":[{"given":"Sarra","family":"Mestiri","sequence":"first","affiliation":[{"name":"Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laila","family":"Assami","sequence":"additional","affiliation":[{"name":"Translational Cancer Research Facility, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeenath Safira K. M.","family":"Yoosuf","sequence":"additional","affiliation":[{"name":"Translational Cancer Research Facility, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]},{"name":"Hamad Bin Khalifa University, Qatar Foundation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Queenie","family":"Fernandes","sequence":"additional","affiliation":[{"name":"Translational Cancer Research Facility, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dina Moustafa","family":"Abo El-Ella","sequence":"additional","affiliation":[{"name":"Translational Cancer Research Facility, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hesham","family":"Elsabah","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maysaloun","family":"Merhi","sequence":"additional","affiliation":[{"name":"Translational Cancer Research Facility, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karama","family":"Makni-Maalej","sequence":"additional","affiliation":[{"name":"Translational Cancer Research Facility, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Honar","family":"Cherif","sequence":"additional","affiliation":[{"name":"Department of Hematology, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]},{"name":"College of Medicine, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Said","family":"Dermime","sequence":"additional","affiliation":[{"name":"Translational Cancer Research Facility, National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]},{"name":"National Center for Cancer Care and Research, Hamad Medical Corporation","place":["Doha, Qatar"]},{"name":"College of Health Sciences, Qatar University","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahab","family":"Uddin","sequence":"additional","affiliation":[{"name":"Translational Research Institute, Academic Health System, Hamad Medical Corporation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fares","family":"Al-Ejeh","sequence":"additional","affiliation":[{"name":"Qatar Biomedical Research Institute, Hamad Bin Khalifa University, Qatar Foundation","place":["Doha, Qatar"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3257","article-title":"The genetic architecture of multiple myeloma","volume":"12","author":"Morgan","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djae321","article-title":"The global multiple myeloma incidence and mortality burden in 2022 and predictions for 2045","volume":"117","author":"Mafra","year":"2025","journal-title":"J Natl Cancer Inst"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)","volume":"28","author":"Ocio","year":"2014","journal-title":"Leukemia"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1200\/edbk_349603","article-title":"Moving toward a cure for myeloma","volume":"42","author":"Mateos","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006540","article-title":"Cancer immunoediting and immune dysregulation in multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-023-03579-x","article-title":"Immune dysregulation in multiple myeloma: the current and future role of cell-based immunotherapy","volume":"117","author":"Russell","year":"2023","journal-title":"Int J Hematol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13040625","article-title":"The immune microenvironment in multiple myeloma: friend or foe","volume":"13","author":"Lopes","year":"2021","journal-title":"Cancers (Basel)"},{"key":"B9","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s10020-018-0051-4","article-title":"Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics","volume":"24","author":"Runcie","year":"2018","journal-title":"Mol Med"},{"key":"B10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13045-023-01482-w","article-title":"Bi- and trispecific immune cell engagers for immunotherapy of hematological Malignancies","volume":"16","author":"Tapia-Galisteo","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/s12943-024-01956-6","article-title":"Efficacy and safety of bispecific antibodies vs. immune checkpoint blockade combination therapy in cancer: a real-world comparison","volume":"23","author":"Cheng","year":"2024","journal-title":"Mol Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023419","article-title":"CAR T cells vs bispecific antibody as third- or later-line large B-cell lymphoma therapy: a meta-analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1207276","article-title":"Natural killer cell engagers (NKCEs): a new frontier in cancer immunotherapy","volume":"14","author":"Zhang","year":"2023","journal-title":"Front Immunol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002393","article-title":"Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma","volume":"4","author":"Pillarisetti","year":"2020","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003805","article-title":"Preclinical activity and determinants of response of the GPRC5DxCD3 bispecific antibody talquetamab in multiple myeloma","volume":"5","author":"Verkleij","year":"2021","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-23-0176","article-title":"An embarrassment of riches: Three FDA-approved bispecific antibodies for relapsed refractory multiple myeloma","volume":"4","author":"Firestone","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"B17","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1056\/nejmoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34756","article-title":"Detailed overview of incidence and management of cytokine release syndrome observed with teclistamab in the MajesTEC-1 study of patients with relapsed\/refractory multiple myeloma","volume":"129","author":"Martin","year":"2023","journal-title":"Cancer"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023616","article-title":"Efficacy and safety of teclistamab in patients with relapsed\/refractory multiple myeloma after BCMA-targeting therapies","volume":"144","author":"Touzeau","year":"2024","journal-title":"Blood"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-023-00989-z","article-title":"Population pharmacokinetics and exposure-response with teclistamab in patients with relapsed\/refractory multiple myeloma: results from MajesTEC-1","volume":"18","author":"Miao","year":"2023","journal-title":"Target Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-026-01205-4","article-title":"Revised recommendations for restarting teclistamab following dose delays: insights from the MajesTEC-1 study on clinical safety, and from simulated pharmacokinetics and cytokine dynamics","author":"Card\u00e9","year":"2026","journal-title":"Targeted Oncol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.70237","article-title":"Efficacy and safety of teclistamab in triple-class exposed relapsed\/refractory multiple myeloma: pooled findings from three clinical cohorts and a retrospective cohort","volume":"132","author":"Martin","year":"2026","journal-title":"Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01149-1","article-title":"Teclistamab dosing in responders: modeling and simulation results from the MajesTEC-1 study in relapsed\/refractory multiple myeloma","volume":"20","author":"Guo","year":"2025","journal-title":"Targeted Oncol"},{"key":"B24","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1007\/s12325-023-02738-0","article-title":"Comparative effectiveness of teclistamab versus real-world physician's choice of therapy in LocoMMotion and MoMMent in triple-class exposed relapsed\/refractory multiple myeloma","volume":"41","author":"Moreau","year":"2024","journal-title":"Adv Ther"},{"key":"B25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.clml.2023.11.001","article-title":"Teclistamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase II MajesTEC-1 study","volume":"24","author":"Martin","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B26","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1002\/cncr.35107","article-title":"Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"130","author":"Nooka","year":"2024","journal-title":"Cancer"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0171","article-title":"Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma","volume":"19","author":"Moreau","year":"2023","journal-title":"Future Oncol"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-022-00893-y","article-title":"Translational modeling predicts efficacious therapeutic dosing range of teclistamab for multiple myeloma","volume":"17","author":"Girgis","year":"2022","journal-title":"Target Oncol"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)01338-6","article-title":"Teclistamab, a B-cell maturation antigen \u00d7 CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MajesTEC-1): a multicenter, open-label, single-arm, phase 1 study","volume":"398","author":"Usmani","year":"2021","journal-title":"Lancet"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-023-02480-7","article-title":"Comparative efficacy of teclistamab versus current treatments in real-world clinical practice in the prospective LocoMMotion study in patients with triple-class-exposed relapsed and\/or refractory multiple myeloma","volume":"40","author":"Moreau","year":"2023","journal-title":"Adv Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023022823","article-title":"Correlation of immune fitness with response to teclistamab in relapsed\/refractory multiple myeloma in the MajesTEC-1 study","volume":"144","author":"Cortes-Selva","year":"2024","journal-title":"Blood"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2406536","article-title":"Talquetamab plus teclistamab in relapsed or refractory multiple myeloma","volume":"392","author":"Cohen","year":"2025","journal-title":"N Engl J Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1080\/14796694.2025.2597732","article-title":"Plain language summary of the management of certain side effects of teclistamab in people with multiple myeloma","volume":"22","author":"Martin","year":"2026","journal-title":"Future Oncol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1182\/bloodadvances.2023011658","article-title":"Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation","volume":"8","author":"Frerichs","year":"2024","journal-title":"Blood Adv"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003342","article-title":"A T-cell-redirecting bispecific G-protein-coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma","volume":"135","author":"Pillarisetti","year":"2020","journal-title":"Blood"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/s2352-3026(24)00385-5","article-title":"Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicenter, open-label, phase 1\u20132 study","volume":"12","author":"Chari","year":"2025","journal-title":"Lancet Hematol"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2204591","article-title":"Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-025-03409-y","article-title":"Comparative efficacy of talquetamab vs. real-world physician's choice of treatment in triple-class-exposed relapsed\/refractory multiple myeloma: updated analyses of MonumenTAL-1 vs. LocoMMotion\/MoMMent","volume":"43","author":"Einsele","year":"2026","journal-title":"Adv Ther"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016613","article-title":"Infections and parameters of humoral immunity with talquetamab in relapsed\/refractory multiple myeloma in MonumenTAL-1","volume":"9","author":"Schinke","year":"2025","journal-title":"Blood Adv"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35927","article-title":"Talquetamab improves patient-reported symptoms and health-related quality of life in relapsed or refractory multiple myeloma: results from the phase 1\/2 MonumenTAL-1 study","volume":"131","author":"Schinke","year":"2025","journal-title":"Cancer"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.soncn.2024.151712","article-title":"Nursing considerations for the clinical management of adverse events associated with talquetamab in patients with relapsed or refractory multiple myeloma","volume":"40","author":"Catamero","year":"2024","journal-title":"Semin Oncol Nurs"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-025-04134-6","article-title":"Talquetamab in Japanese patients with relapsed\/refractory multiple myeloma in the MonumenTAL-1 study","volume":"123","author":"Ito","year":"2026","journal-title":"Int J Hematol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.71276","article-title":"Characterization and management of cytokine release syndrome from the MonumenTAL-1 study of talquetamab in patients with relapsed\/refractory multiple myeloma","volume":"14","author":"van de Donk","year":"2025","journal-title":"Cancer Med"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02797-x","article-title":"Comparative efficacy of talquetamab vs. current treatments in the LocoMMotion and MoMMent studies in patients with triple-class-exposed relapsed\/refractory multiple myeloma","volume":"41","author":"Einsele","year":"2024","journal-title":"Adv Ther"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2025.2514909","article-title":"Cost per responder for teclistamab and elranatamab in relapsed or refractory multiple myeloma in the United States","volume":"28","author":"Gordan","year":"2025","journal-title":"J Med Econ"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2026.03.014","article-title":"Comparison of patient-reported outcomes for elranatamab in MagnetisMM-3 versus real-world physician choice of therapy for triple-class refractory multiple myeloma","author":"Hebraud","year":"2026","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01170-4","article-title":"Elranatamab fixed dosing: a safe, effective, and convenient dosing approach","volume":"20","author":"Elmeliegy","year":"2025","journal-title":"Target Oncol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01134-8","article-title":"Dose optimization of elranatamab to mitigate the risk of cytokine release syndrome in patients with multiple myeloma","volume":"20","author":"Elmeliegy","year":"2025","journal-title":"Target Oncol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1182\/blood-2023-185920","article-title":"A matching-adjusted indirect comparison of the efficacy of elranatamab versus physician's choice of treatment in patients with triple-class exposed\/refractory multiple myeloma","volume":"40","author":"Mol","year":"2024","journal-title":"Curr Med Res Opin"},{"key":"B51","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/jjco\/hyae068","article-title":"Elranatamab in Japanese patients with relapsed\/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3","volume":"54","author":"Iida","year":"2024","journal-title":"Jpn J Clin Oncol"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-025-01168-y","article-title":"Population exposure\u2013response efficacy analysis of elranatamab (PF-06863135) in patients with multiple myeloma","volume":"20","author":"Lon","year":"2025","journal-title":"Targeted Oncol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.2217\/fon-2023-0995","article-title":"Elranatamab efficacy in MagnetisMM-3 compared with real-world control arms in triple-class refractory multiple myeloma","volume":"20","author":"Costa","year":"2024","journal-title":"Future Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/jjco\/hyae068","article-title":"Elranatamab in Japanese patients with relapsed\/refractory multiple myeloma: results from MagnetisMM-2 and MagnetisMM-3","volume":"54","author":"Iida","year":"2024","journal-title":"Jpn J Clin Oncol."},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.1200\/jco.24.01008","article-title":"Linvoseltamab for treatment of relapsed\/refractory multiple myeloma","volume":"42","author":"Bumma","year":"2024","journal-title":"J Clin Oncol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"e201","DOI":"10.1016\/j.clml.2025.11.004","article-title":"Linvoseltamab in patients with relapsed\/refractory multiple myeloma in the LINKER-MM1 study: longer follow-up and subgroup analyses","volume":"26","author":"Lee","year":"2026","journal-title":"Clin Lymphoma Myeloma Leukemia"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025987","article-title":"Forimtamig, a novel GPRC5D-targeting T-cell bispecific antibody with a 2 + 1 format, for the treatment of multiple myeloma","volume":"145","author":"Eckmann","year":"2025","journal-title":"Blood"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00821-1","article-title":"ISB 2001 trispecific T cell engager shows strong tumor cytotoxicity and overcomes immune escape mechanisms of multiple myeloma cells","volume":"5","author":"Carretero-Iglesia","year":"2024","journal-title":"Nat Cancer"},{"key":"B59","doi-asserted-by":"publisher","first-page":"TPS2668","DOI":"10.1891\/9780826155146.0036","article-title":"GNC-038, a tetra-specific antibody, in patients with R\/R non-Hodgkin lymphoma or acute lymphoblastic leukemia: a phase 1 study design and rationale","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1016\/b978-0-12-821584-5.00012-2","article-title":"Four-in-one antibodies have superior cancer inhibitory activity against EGFR, HER2, HER3, and VEGF through disruption of HER\/MET crosstalk","volume":"75","author":"Hu","year":"2015","journal-title":"Cancer Res"},{"key":"B61","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1038\/s41375-020-0734-z","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: rationale for targeting and current therapeutic approaches","volume":"34","author":"Shah","year":"2020","journal-title":"Leukemia"},{"key":"B62","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41408-020-0337-y","article-title":"B-cell maturation antigen expression across hematologic cancers: a systematic literature review","volume":"10","author":"Dogan","year":"2020","journal-title":"Blood Cancer J"},{"key":"B63","doi-asserted-by":"publisher","first-page":"7540","DOI":"10.1016\/s2152-2650(24)00953-4","article-title":"Long-term follow-up from the phase 1\/2 MajesTEC-1 trial of teclistamab in patients with relapsed\/refractory multiple myeloma","volume":"42","author":"Garfall","year":"2024","journal-title":"J Clin Oncol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.8049","article-title":"Evaluating the efficacy of commercial teclistamab in relapsed refractory multiple myeloma patients with prior exposure to anti-BCMA therapies","volume":"41","author":"Firestone","year":"2023","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-06078-z","article-title":"Efficacy and safety of teclistamab in relapsed or refractory multiple myeloma: a systematic review and meta-analysis","volume":"103","author":"Qureshi","year":"2024","journal-title":"Ann Hematol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2514663","article-title":"Teclistamab plus daratumumab in relapsed or refractory multiple myeloma","volume":"394","author":"Costa","year":"2026","journal-title":"N Engl J Med"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.136","article-title":"Long-term survival and safety of elranatamab in patients with relapsed or refractory multiple myeloma: update from the MagnetisMM-3 study","volume":"8","author":"Tomasson","year":"2024","journal-title":"Hemasphere"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02589-w","article-title":"Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial","volume":"29","author":"Bahlis","year":"2023","journal-title":"Nat Med"},{"key":"B69","doi-asserted-by":"publisher","first-page":"3265","DOI":"10.1182\/blood-2024-208776","article-title":"Characterization of linvoseltamab's BCMA binding epitope and efficacy against BCMA mutations in relapsed\/refractory multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-ct013","article-title":"Abstract CT013: Safety and efficacy from the phase 1\/2 first-in-human study of REGN5459, a BCMA\u00d7CD3 bispecific antibody with low CD3 affinity, in patients with relapsed\/refractory multiple myeloma","volume":"83","author":"Suvannasankha","year":"2023","journal-title":"Cancer Res"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-210376","article-title":"Comparative effectiveness of linvoseltamab versus current real-world standard of care therapies in triple-class exposed relapsed\/refractory multiple myeloma treated at IMWG sites","volume":"144","author":"Kumar","year":"2024","journal-title":"Blood"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002736","article-title":"A BCMAxCD3 bispecific T cell-engaging antibody demonstrates robust antitumor efficacy similar to that of anti-BCMA CAR T cells","volume":"5","author":"DiLillo","year":"2021","journal-title":"Blood Adv"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-167008","article-title":"A phase 1 first-in-human study of Abbv-383, a BCMA x CD3 bispecific T-cell-redirecting antibody, as monotherapy in patients with relapsed\/refractory multiple myeloma","volume":"140","author":"Voorhees","year":"2022","journal-title":"Blood"},{"key":"B74","doi-asserted-by":"publisher","first-page":"4666","DOI":"10.1182\/blood-2023-179039","article-title":"Bivalent BCMA binding and low affinity CD3 T-cell engagement by Abbv-383 drives sustained activation with reduced T-cell exhaustion in preclinical models of multiple myeloma","volume":"142","author":"Sharon","year":"2023","journal-title":"Blood"},{"key":"B75","doi-asserted-by":"publisher","first-page":"3378","DOI":"10.1182\/blood-2023-182388","article-title":"Updated safety and efficacy results of Abbv-383, a BCMA x CD3 bispecific T-cell redirecting antibody, in a first-in-human phase 1 study in patients with relapsed\/refractory multiple myeloma","volume":"142","author":"Vij","year":"2023","journal-title":"Blood"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.8038","article-title":"Results from a first-in-human phase I study of F182112, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"41","author":"Sun","year":"2023","journal-title":"J Clin Oncol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1182\/blood-2022-159009","article-title":"Alnuctamab (ALNUC; BMS-986349; CC-93269), a 2 + 1 B-cell maturation antigen (BCMA) x CD3 T-cell engager (TCE), administered subcutaneously (SC) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated results from a phase 1 first-in-human clinical study","volume":"142","author":"Bar","year":"2023","journal-title":"Blood"},{"key":"B78","doi-asserted-by":"publisher","first-page":"3377","DOI":"10.1182\/blood-2023-187242","article-title":"Updated results of talquetamab, a GPRC5D\u00d7CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma with prior exposure to T-cell redirecting therapies: results of the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Jakubowiak","year":"2023","journal-title":"Blood"},{"key":"B79","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/s41408-025-01386-7","article-title":"Talquetamab in relapsed refractory multiple myeloma: multi-institutional real-world study","volume":"15","author":"Al Hadidi","year":"2025","journal-title":"Blood Cancer J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157988","article-title":"RG6234, a GPRC5DxCD3 T-cell engaging bispecific antibody, is highly active in patients (pts) with relapsed\/refractory multiple myeloma (RRMM): updated intravenous (IV) and first subcutaneous (SC) results from a phase I dose-escalation study","volume":"140","author":"Carlo-Stella","year":"2022","journal-title":"Blood"},{"key":"B81","doi-asserted-by":"publisher","first-page":"4672","DOI":"10.1182\/blood-2023-181395","article-title":"Lbl-034, a highly differentiated T-cell engaging bispecific antibody targeting GPRC5D for the treatment of relapsed or refractory multiple myeloma","volume":"142","author":"Wang","year":"2023","journal-title":"Blood"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-202871","article-title":"An uniquely designed asymmetric bispecific antibody against GPRC5D and CD3 (LBL-034) in patients with relapsed\/refractory multiple myeloma: A phase I\/II, first in human, open-label, multicenter, dose escalation\/expansion study","volume":"144","author":"Qin","year":"2024","journal-title":"Blood"},{"key":"B83","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1038\/s41467-023-39395-4","article-title":"Chimeric antigen receptor T cells targeting FcRH5 provide robust tumor-specific responses in murine xenograft models of multiple myeloma","volume":"14","author":"Jiang","year":"2023","journal-title":"Nat Commun"},{"key":"B84","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1182\/blood-2021-147983","article-title":"Cevostamab monotherapy continues to show clinically meaningful activity and manageable safety in patients with heavily pre-treated relapsed\/refractory multiple myeloma (RRMM): Updated results from an ongoing phase I study","volume":"138","author":"Trudel","year":"2021","journal-title":"Blood"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157547","article-title":"Enduring responses after 1-year, fixed-duration cevostamab therapy in patients with relapsed\/refractory multiple myeloma: Early experience from a phase I study","volume":"140","author":"Lesokhin","year":"2022","journal-title":"Blood"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000970688.75458.a8","article-title":"P946: Tocilizumab pre-treatment significantly reduces the incidence of cytokine release syndrome in patients with relapsed\/refractory multiple myeloma (Rrmm) who receive cevostamab","volume":"7","author":"Mateos","year":"2023","journal-title":"HemaSphere"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2025016911","article-title":"Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies","volume":"9","author":"Kowalski","year":"2025","journal-title":"Blood Adv"},{"key":"B88","doi-asserted-by":"publisher","first-page":"TPS8064","DOI":"10.1200\/jco.2023.41.16_suppl.tps8064","article-title":"CAMMA 2: A phase I\/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed\/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent","volume":"41","author":"Kumar","year":"2023","journal-title":"J Clin Oncol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022019451","article-title":"Preclinical characterization of ISB 1342, a CD38 x CD3 T-cell engager for relapsed\/refractory multiple myeloma","volume":"142","author":"Pouleau","year":"2023","journal-title":"Blood"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157525","article-title":"Initial results of dose escalation of ISB 1342, a novel CD3xCD38 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Mohan","year":"2022","journal-title":"Blood"},{"key":"B91","doi-asserted-by":"publisher","first-page":"3339","DOI":"10.1182\/blood-2023-186664","article-title":"Dose escalation of ISB 1342, a novel CD38xCD3 bispecific antibody, in patients with relapsed \/ refractory multiple myeloma (RRMM)","volume":"142","author":"Kapoor","year":"2023","journal-title":"Blood"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.mct-23-0052","article-title":"CD38 x ICAM-1 bispecific antibody is a novel approach for treating multiple myeloma and lymphoma","volume":"23","author":"Chen","year":"2024","journal-title":"Mol Cancer Ther"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-18-2752","article-title":"Targeting multiple myeloma with AMG 424, a novel anti-CD38\/CD3 bispecific T-cell-recruiting antibody optimized for cytotoxicity and cytokine release","volume":"25","author":"Zuch de Zafra","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159205","article-title":"Igm-2644, a novel CD38xCD3 bispecific IgM T cell engager demonstrates potent efficacy on myeloma cells with an improved preclinical safety profile","volume":"140","author":"Li","year":"2022","journal-title":"Blood"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159665","article-title":"Updated interim results from a phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC\u00ae) targeting B cell maturation antigen (BCMA) for relapsed\/refractory multiple myeloma (RRMM)","volume":"140","author":"Abdallah","year":"2022","journal-title":"Blood"},{"key":"B96","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1182\/blood-2023-182345","article-title":"Results from the completed dose escalation portion of the phase 1 study of HPN217, a half-life extended tri-specific T cell activating construct (TriTAC) targeting B cell maturation antigen (BCMA) for relapsed\/refractory multiple myeloma (MM)","volume":"142","author":"Madan","year":"2023","journal-title":"Blood"},{"key":"B97","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1182\/blood-2023-174941","article-title":"Characterization of JNJ-79635322, a novel BCMAxGPRC5DxCD3 T-cell redirecting trispecific antibody, for the treatment of multiple myeloma","volume":"142","author":"Pillarisetti","year":"2023","journal-title":"Blood"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0519-4","article-title":"Dynamic CD138 surface expression regulates switch between myeloma growth and dissemination","volume":"34","author":"Akhmetzyanova","year":"2020","journal-title":"Leukemia"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.3109\/08923973.2016.1153110","article-title":"Anti-human CD138 monoclonal antibodies and their bispecific formats: Generation and characterization","volume":"38","author":"Chen","year":"2016","journal-title":"Immunopharmacol Immunotoxicol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011647","article-title":"Comparison of antibody-based immunotherapeutics for Malignant hematological disease in an experimental murine model","volume":"8","author":"Frebel","year":"2024","journal-title":"Blood Adv"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-09-3707","article-title":"NY-ESO-1 is highly expressed in poor-prognosis multiple myeloma and induces spontaneous humoral and cellular immune responses","volume":"105","author":"van Rhee","year":"2005","journal-title":"Blood"},{"key":"B102","doi-asserted-by":"publisher","first-page":"13293","DOI":"10.1038\/s41598-019-49834-2","article-title":"Direct comparison of target-reactivity and cross-reactivity induced by CAR- and BiTE-redirected T cells for the development of antibody-based T-cell therapy","volume":"9","author":"Maruta","year":"2019","journal-title":"Sci Rep"},{"key":"B103","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1038\/s42003-020-01558-0","article-title":"Combinatorial targeting of multiple myeloma by complementing T cell engaging antibody fragments","volume":"4","author":"Geis","year":"2021","journal-title":"Commun Biol"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1158\/2767-9764.crc-23-0434","article-title":"Ex vivo efficacy of SAR442257 anti-CD38 trispecific T-cell engager in multiple myeloma relapsed after daratumumab and BCMA-targeted therapies","volume":"4","author":"Keller","year":"2024","journal-title":"Cancer Res Commun"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-024-01176-4","article-title":"Bridging the gap with multispecific immune cell engagers in cancer and infectious diseases","volume":"21","author":"Rolin","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.70046","article-title":"Natural killer cell engagers: From bi-specific to tri-specific and tetra-specific engagers for enhanced cancer immunotherapy","volume":"14","author":"Zhu","year":"2024","journal-title":"Clin Transl Med"},{"key":"B107","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1038\/s41392-023-01452-1","article-title":"Macrophages in immunoregulation and therapeutics","volume":"8","author":"Chen","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23010164","article-title":"Challenges and recent advances in NK cell-targeted immunotherapies in solid tumors","volume":"23","author":"Lian","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B109","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1186\/s13045-022-01328-x","article-title":"Targeting macrophages in hematological Malignancies: Recent advances and future directions","volume":"15","author":"Li","year":"2022","journal-title":"J Hematol Oncol"},{"key":"B110","doi-asserted-by":"publisher","first-page":"357ra123","DOI":"10.1126\/scitranslmed.aaf2341","article-title":"Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia","volume":"8","author":"Romee","year":"2016","journal-title":"Sci Transl Med"},{"key":"B111","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1016\/j.cell.2018.10.014","article-title":"Anti-NKG2A mAb is a checkpoint inhibitor that promotes anti-tumor immunity by unleashing both T and NK cells","volume":"175","author":"Andr\u00e9","year":"2018","journal-title":"Cell"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.37349\/etat.2024.00227","article-title":"Tri-specific killer engager: Unleashing multi-synergic power against cancer","volume":"5","author":"Winidmanokul","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01478-w","article-title":"A BCMA\/CD16A bispecific innate cell engager for the treatment of multiple myeloma","volume":"36","author":"Kakiuchi-Kiyota","year":"2022","journal-title":"Leukemia"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2020-4556","article-title":"Abstract 4556: Preclinical pharmacology and safety of RO7297089, a novel anti-BCMA\/CD16a bispecific antibody for the treatment of multiple myeloma","volume":"80","author":"Kakiuchi-Kiyota","year":"2020","journal-title":"Cancer Res"},{"key":"B115","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1208\/s12248-022-00744-8","article-title":"Nonclinical pharmacokinetics, pharmacodynamics, and translational model of RO7297089, a novel anti-BCMA\/CD16A bispecific tetravalent antibody for the treatment of multiple myeloma","volume":"24","author":"Cai","year":"2022","journal-title":"AAPS J"},{"key":"B116","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/s44228-022-00023-5","article-title":"Phase I study of safety and pharmacokinetics of RO7297089, an anti-BCMA\/CD16a bispecific antibody, in patients with relapsed, refractory multiple myeloma","volume":"5","author":"Plesner","year":"2023","journal-title":"Clin Hematol Int"},{"key":"B117","doi-asserted-by":"publisher","first-page":"2755","DOI":"10.1182\/blood-2021-147418","article-title":"A phase I study of RO7297089, a B-cell maturation antigen (BCMA)-CD16a bispecific antibody in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"138","author":"Plesner","year":"2021","journal-title":"Blood"},{"key":"B118","doi-asserted-by":"publisher","first-page":"2054","DOI":"10.1038\/s41467-024-46310-y","article-title":"Development of ISB 1442, a CD38 and CD47 bispecific biparatopic antibody innate cell modulator for the treatment of multiple myeloma","volume":"15","author":"Grandclement","year":"2024","journal-title":"Nat Commun"},{"key":"B119","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1182\/blood-2021-145586","article-title":"ISB 1442, a first-in-class CD38 and CD47 bispecific antibody innate cell modulator for the treatment of relapsed refractory multiple myeloma","volume":"138","author":"Stefano","year":"2021","journal-title":"Blood"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2012.141","article-title":"Anti-CD47 antibodies promote phagocytosis and inhibit the growth of human myeloma cells","volume":"26","author":"Kim","year":"2012","journal-title":"Leukemia"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.01380","article-title":"Therapeutic targeting of the macrophage immune checkpoint CD47 in myeloid Malignancies","volume":"9","author":"Chao","year":"2019","journal-title":"Front Oncol"},{"key":"B122","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s40364-023-00456-x","article-title":"The landscape overview of CD47-based immunotherapy for hematological Malignancies","volume":"11","author":"Yang","year":"2023","journal-title":"biomark Res"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02018","article-title":"First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J Clin Oncol"},{"key":"B124","doi-asserted-by":"publisher","first-page":"4707","DOI":"10.1182\/blood-2023-186241","article-title":"Initial dose escalation of ISB 1442, a novel CD38 biparatopic x CD47 bispecific antibody, in patients with relapsed \/ refractory multiple myeloma (RRMM)","volume":"142","author":"Kazandjian","year":"2023","journal-title":"Blood"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-166187","article-title":"The novel trifunctional anti-BCMA NK cell engager SAR'514 has potent in-vitro and in-vivo anti-myeloma effect through dual NK cell engagement","volume":"140","author":"Tang","year":"2022","journal-title":"Blood"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2026.102628","article-title":"Targeting BCMA in multiple myeloma with a trifunctional NK cell engager","volume":"7","author":"Tang","year":"2026","journal-title":"Cell Rep Med"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2017.35.15_suppl.8045","article-title":"AFM26 is a novel, highly potent BCMA\/CD16A-directed bispecific antibody for high affinity NK-cell engagement in multiple myeloma","volume":"35","author":"Gantke","year":"2017","journal-title":"J Clin Oncol"},{"key":"B128","doi-asserted-by":"publisher","first-page":"3082","DOI":"10.1182\/blood.V130.Suppl_1.3082.3082","article-title":"AFM26-targeting B cell maturation antigen (BCMA) for NK cell-mediated immunotherapy of multiple myeloma","volume":"130","author":"Gantke","year":"2017","journal-title":"Blood"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1182\/blood-2018-99-118970","article-title":"Preclinical characterization of AFM26, a novel B cell maturation antigen (BCMA)-directed tetravalent bispecific antibody for high affinity retargeting of NK cells against myeloma","volume":"132","author":"Ross","year":"2018","journal-title":"Blood"},{"key":"B130","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s40364-021-00332-6","article-title":"A comprehensive comparison between camelid nanobodies and single chain variable fragments","volume":"9","author":"Asaadi","year":"2021","journal-title":"biomark Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"6211","DOI":"10.1038\/s41467-024-50474-y","article-title":"Orchestrating NK and T cells via tri-specific nano-antibodies for synergistic antitumor immunity","volume":"15","author":"Ye","year":"2024","journal-title":"Nat Commun"},{"key":"B132","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1038\/s41392-023-01523-3","article-title":"Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy","volume":"8","author":"Yang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbt.2023.09.002","article-title":"Affibody-based hBCMA x CD16 dual engagers for NK cell-mediated killing of multiple myeloma cells","volume":"77","author":"Giang","year":"2023","journal-title":"N Bio\/Technol"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1155\/crh\/8425047","article-title":"A case report supporting the use of teclistamab in multiple myeloma with CNS involvement","volume":"2025","author":"Blackman","year":"2025","journal-title":"Case Rep Hematol"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.70108","article-title":"Bispecific antibody therapy in CNS myeloma: Early evidence from a multicenter cohort","volume":"207","author":"Noveihed","year":"2025","journal-title":"Br J Haematol"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2019-4972","article-title":"Abstract 4972: Preclinical development of a first-in-class NKp30xBCMA NK cell engager for the treatment of multiple myeloma","volume":"79","author":"Draghi","year":"2019","journal-title":"Cancer Res"},{"key":"B137","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1182\/blood-2019-128749","article-title":"CTX-8573, an innate-cell engager targeting BCMA, is a highly potent multispecific antibody for the treatment of multiple myeloma","volume":"134","author":"Watkins-Yoon","year":"2019","journal-title":"Blood"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.5135","article-title":"HER2-specific immunoligands engaging NKp30 or NKp80 trigger NK-cell-mediated lysis of tumor cells and enhance antibody-dependent cell-mediated cytotoxicity","volume":"6","author":"Peipp","year":"2015","journal-title":"Oncotarget"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2007.01.013","article-title":"Cytokine-driven regulation of NK cell functions in tumor immunity: role of the MICA-NKG2D system","volume":"18","author":"Zwirner","year":"2007","journal-title":"Cytokine Growth Factor Rev"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1230","article-title":"NKG2D and MICA\/B shedding: a 'tag game' between NK cells and Malignant cells","volume":"9","author":"Xing","year":"2020","journal-title":"Clin Transl Immunol"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1097\/cji.0000000000000320","article-title":"BCMA-targeting bispecific antibody that simultaneously stimulates NKG2D-enhanced efficacy against multiple myeloma","volume":"43","author":"Wang","year":"2020","journal-title":"J Immunother"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.21203\/rs.3.rs-351031\/v1","article-title":"BCMA targets bispecific fusion protein for induction of NK cell activity against multiple myeloma","author":"Xu","year":"2021"},{"key":"B143","doi-asserted-by":"publisher","first-page":"6725","DOI":"10.1182\/blood-2023-190613","article-title":"CYT-338 NK cell engager mutispecific antibody engagement of NKp46 activation receptor overcomes anti-CD38 Mab mediated fratricide of NK cells and accords enhanced cancer immunotherapy","volume":"142","author":"Khairnar","year":"2023","journal-title":"Blood"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-170193","article-title":"Biological characterization and differential gene expression analysis of CYT-338 NK cell engager (NKE) against CD38 expressing tumors including multiple myeloma (MM)","volume":"140","author":"Lin","year":"2022","journal-title":"Blood"},{"key":"B145","unstructured":""},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.cir-17-0649","article-title":"A CS1-NKG2D bispecific antibody collectively activates cytolytic immune cells against multiple myeloma","volume":"6","author":"Chan","year":"2018","journal-title":"Cancer Immunol Res"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.635173","article-title":"Harnessing and enhancing macrophage phagocytosis for cancer therapy","volume":"12","author":"Chen","year":"2021","journal-title":"Front Immunol"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1007\/s00281-022-00966-0","article-title":"Tumor microenvironment antigens","volume":"45","author":"Andersen","year":"2023","journal-title":"Semin Immunopathol"},{"key":"B149","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000843624.82943.92","article-title":"S183: Novel combination immunotherapy for the treatment of relapsed\/refractory multiple myeloma: Updated phase 1b results for talquetamab (a Gprc5d x Cd3 bispecific antibody) in combination with daratumumab","volume":"6","author":"van de Donk","year":"2022","journal-title":"HemaSphere"},{"key":"B150","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000843612.41180.42","article-title":"S180: Rg6234, a novel Gprc5d T-cell engaging bispecific antibody, induces rapid responses in patients with relapsed\/refractory multiple myeloma: Preliminary results from a first-in-human trial","volume":"6","author":"Hasselbalch Riley","year":"2022","journal-title":"HemaSphere"},{"key":"B151","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159707","article-title":"Talquetamab, a G protein-coupled receptor family C group 5 member D x CD3 bispecific antibody, in patients with relapsed\/refractory multiple myeloma (RRMM): Phase 1\/2 results from MonumenTAL-1","volume":"140","author":"Chari","year":"2022","journal-title":"Blood"},{"key":"B152","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2025.2570748","article-title":"Improving dual targeting selectivity in T-cell engagers via synapse-gated and affinity-tuned trispecific antibody design","volume":"17","author":"Zhao","year":"2025","journal-title":"MAbs"},{"key":"B153","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1038\/s43018-023-00536-9","article-title":"Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors","volume":"4","author":"Cattaruzza","year":"2023","journal-title":"Nat Cancer"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-physiol-021119-034627","article-title":"The acidic tumor microenvironment as a driver of cancer","volume":"82","author":"Boedtkjer","year":"2020","journal-title":"Annu Rev Physiol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1080\/19420862.2024.2322562","article-title":"A novel conditional active biologic anti-EpCAM x anti-CD3 bispecific antibody with synergistic tumor selectivity for cancer immunotherapy","volume":"16","author":"Frey","year":"2024","journal-title":"MAbs"},{"key":"B156","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines8070204","article-title":"Bi- and tri-specific T cell engager-armed oncolytic viruses: Next-generation cancer immunotherapy","volume":"8","author":"Guo","year":"2020","journal-title":"Biomedicines"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.3390\/medicina61122113","article-title":"Mechanistic insights and advances of bispecific T cell engaging antibodies therapy in multiple myeloma","volume":"61","author":"Tang","year":"2025","journal-title":"Med (Kaunas)"},{"key":"B158","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.1c00208","article-title":"Incorporation of a novel CD16-specific single-domain antibody into multispecific natural killer cell engagers with potent ADCC","volume":"18","author":"van Faassen","year":"2021","journal-title":"Mol Pharm"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front Immunol"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1016\/j.jconrel.2019.02.016","article-title":"Current strategies in extending half-lives of therapeutic proteins","volume":"301","author":"Zaman","year":"2019","journal-title":"J Control Release"},{"key":"B161","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.838406","article-title":"Half-life extended nanobody-based CD38-specific bispecific killercell engagers induce killing of multiple myeloma cells","volume":"13","author":"Hambach","year":"2022","journal-title":"Front Immunol"},{"key":"B162","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1186\/s13045-023-01507-4","article-title":"Nanobody-based trispecific T cell engager (Nb-TriTE) enhances therapeutic efficacy by overcoming tumor-mediated immunosuppression","volume":"16","author":"Ding","year":"2023","journal-title":"J Hematol Oncol"},{"key":"B163","doi-asserted-by":"publisher","DOI":"10.1016\/j.nantod.2021.101313","article-title":"Bi-specific macrophage nano-engager for cancer immunotherapy","volume":"41","author":"Zhao","year":"2021","journal-title":"Nano Today"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1007\/s11899-024-00740-z","article-title":"Management of toxicities associated with BCMA, GPRC5D, and FcRH5-targeting bispecific antibodies in multiple myeloma","volume":"19","author":"Pan","year":"2024","journal-title":"Curr Hematol Malig Rep"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.18909","article-title":"Recommendations on prevention of infections during chimeric antigen receptor T-cell and bispecific antibody therapy in multiple myeloma","volume":"203","author":"Mohan","year":"2023","journal-title":"Br J Haematol"},{"key":"B166","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol"},{"key":"B167","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2023.112986","article-title":"Practical guidelines for the management of adverse events of the T cell engager bispecific tebentafusp","volume":"191","author":"Hassel","year":"2023","journal-title":"Eur J Cancer"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.3390\/curroncol32040238","article-title":"Perspectives on outpatient delivery of bispecific T-cell engager therapies for multiple myeloma","volume":"32","author":"Pelland","year":"2025","journal-title":"Curr Oncol"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.1080\/2162402x.2022.2083479","article-title":"Novel strategies for the mitigation of cytokine release syndrome induced by T cell engaging therapies with a focus on the use of kinase inhibitors","volume":"11","author":"Leclercq","year":"2022","journal-title":"Oncoimmunology"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1038\/s41423-020-0417-8","article-title":"Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics","volume":"17","author":"Li","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"B171","doi-asserted-by":"publisher","DOI":"10.1002\/cyto.a.20859","article-title":"Evaluation of a 12-color flow cytometry panel to study lymphocyte, monocyte, and dendritic cell subsets in humans","volume":"77","author":"Autissier","year":"2010","journal-title":"Cytometry A"},{"key":"B172","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06816-9","article-title":"Dictionary of immune responses to cytokines at single-cell resolution","volume":"625","author":"Cui","year":"2024","journal-title":"Nature"},{"key":"B173","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a016303","article-title":"The chemokine system in innate immunity","volume":"7","author":"Sokol","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2023.2256904","article-title":"Principles and current clinical landscape of NK cell engaging bispecific antibody against cancer","volume":"19","author":"Huan","year":"2023","journal-title":"Hum Vaccin Immunother"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2021.06.018","article-title":"Anti-NKG2C\/IL-15\/anti-CD33 killer engager directs primary and iPSC-derived NKG2C(+) NK cells to target myeloid leukemia","volume":"29","author":"Chiu","year":"2021","journal-title":"Mol Ther"},{"key":"B176","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.3223","article-title":"Impact of treatment modality and route of administration on cytokine release syndrome in relapsed or refractory multiple myeloma: A meta-analysis","volume":"115","author":"Soltantabar","year":"2024","journal-title":"Clin Pharmacol Ther"},{"key":"B177","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16132337","article-title":"Bispecific antibodies for the management of relapsed\/refractory multiple myeloma","volume":"16","author":"Tacchetti","year":"2024","journal-title":"Cancers (Basel)"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-024-02985-9","article-title":"Differences between intravenous and subcutaneous modes of administration in oncology from the patient, healthcare provider, and healthcare system perspectives: A systematic review","volume":"41","author":"Aguiar-Ibanez","year":"2024","journal-title":"Adv Ther"},{"key":"B179","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02491-5","article-title":"Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma","volume":"29","author":"Lee","year":"2023","journal-title":"Nat Med"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-21-0038","article-title":"Tumor burden limits bispecific antibody efficacy through T cell exhaustion averted by concurrent cytotoxic therapy","volume":"2","author":"Meermeier","year":"2021","journal-title":"Blood Cancer Discov"},{"key":"B181","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1038\/s41408-024-01081-z","article-title":"Clinical features associated with poor response and early relapse following BCMA-directed therapies in multiple myeloma","volume":"14","author":"Rees","year":"2024","journal-title":"Blood Cancer J"},{"key":"B182","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1182\/blood-2021-144921","article-title":"Early, deep, and durable responses, and low rates of cytokine release syndrome with REGN5458, a BCMAxCD3 bispecific monoclonal antibody, in a phase 1\/2 first-in-human study in patients with relapsed\/refractory multiple myeloma (RRMM)","volume":"138","author":"Zonder","year":"2021","journal-title":"Blood"},{"key":"B183","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1182\/blood-2023-187755","article-title":"Mechanisms of resistance and relapse with talquetamab in patients with relapsed\/refractory multiple myeloma from the phase 1\/2 MonumenTAL-1 study","volume":"142","author":"Vishwamitra","year":"2023","journal-title":"Blood"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007923","article-title":"Sequencing T-cell redirection therapies leads to deep and durable responses in patients with relapsed\/refractory myeloma","volume":"7","author":"Mouhieddine","year":"2023","journal-title":"Blood Adv"},{"key":"B185","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2024012773","article-title":"A research center's experience of T-cell-redirecting therapies in triple-class refractory multiple myeloma","volume":"8","author":"Puertas","year":"2024","journal-title":"Blood Adv"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-19-2299","article-title":"Preclinical activity of JNJ-7957, a novel BCMAxCD3 bispecific antibody for the treatment of multiple myeloma, is potentiated by daratumumab","volume":"26","author":"Frerichs","year":"2020","journal-title":"Clin Cancer Res"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012354","article-title":"Mechanisms of resistance to bispecific T-cell engagers in multiple myeloma and their clinical implications","volume":"8","author":"Letouz\u00e9","year":"2024","journal-title":"Blood Adv"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011242","article-title":"Immune status and selection of patients for immunotherapy in myeloma: a proposal","volume":"8","author":"Dhodapkar","year":"2024","journal-title":"Blood Adv"},{"key":"B189","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002565","article-title":"AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys","volume":"4","author":"Goldstein","year":"2020","journal-title":"Blood Adv"},{"key":"B190","doi-asserted-by":"publisher","first-page":"5135","DOI":"10.1038\/s41598-024-55143-0","article-title":"A novel T cell-redirecting anti-GPRC5D x CD3 bispecific antibody with potent antitumor activity in multiple myeloma preclinical models","volume":"14","author":"Tomita","year":"2024","journal-title":"Sci Rep"},{"key":"B191","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.02.001","article-title":"Membrane-proximal epitope facilitates efficient T cell synapse formation by anti-FcRH5\/CD3 and is a requirement for myeloma cell killing","volume":"31","author":"Li","year":"2017","journal-title":"Cancer Cell"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007625","article-title":"Effects of teclistamab and talquetamab on soluble BCMA levels in patients with relapsed\/refractory multiple myeloma","volume":"7","author":"Girgis","year":"2023","journal-title":"Blood Adv"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024026212","article-title":"Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myeloma","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"key":"B195","doi-asserted-by":"publisher","DOI":"10.1200\/jco.19.02657","article-title":"Anti-B-cell maturation antigen BiTE molecule AMG 420 induces responses in multiple myeloma","volume":"38","author":"Topp","year":"2020","journal-title":"J Clin Oncol"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.3389\/pore.2023.1611171","article-title":"Soluble B-cell maturation antigen as a monitoring marker for multiple myeloma","volume":"29","author":"Wiedemann","year":"2023","journal-title":"Pathol Oncol Res"},{"key":"B197","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2023023557","article-title":"Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma","volume":"144","author":"Firestone","year":"2024","journal-title":"Blood"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.3390\/cancers18040686","article-title":"Soluble B-cell maturation antigen as a prognostic marker for progression-free survival in multiple myeloma treated with BCMA-directed therapies: a systematic review and meta-analysis","volume":"18","author":"Borkowski","year":"2026","journal-title":"Cancers"},{"key":"B199","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1038\/s41408-022-00716-3","article-title":"Gamma-secretase inhibitors augment efficacy of BCMA-targeting bispecific antibodies against multiple myeloma cells without impairing T-cell activation and differentiation","volume":"12","author":"Chen","year":"2022","journal-title":"Blood Cancer J"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2023-5081","article-title":"Abstract 5081: Anti-tumor activity of HPN217, a BCMA-targeting tri-specific T cell engager, is enhanced by \u03b3-secretase inhibitors in preclinical models","volume":"83","author":"Laurie","year":"2023","journal-title":"Cancer Res"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-023-00625-9","article-title":"Acquired resistance to a GPRC5D-directed T-cell engager in multiple myeloma is mediated by genetic or epigenetic target inactivation","volume":"4","author":"Derrien","year":"2023","journal-title":"Nat Cancer"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021004418","article-title":"Single- and double-hit events in genes encoding immune targets before and after T cell-engaging antibody therapy in MM","volume":"5","author":"Truger","year":"2021","journal-title":"Blood Adv"},{"key":"B203","doi-asserted-by":"publisher","DOI":"10.1158\/2643-3230.bcd-25-0005","article-title":"Timing genomic antigen loss in multiple myeloma treated with T cell-redirecting immunotherapies","volume":"6","author":"Papadimitriou","year":"2025","journal-title":"Blood Cancer Discov"},{"key":"B204","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1016\/j.ccell.2017.02.002","article-title":"Target expression, generation, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment","volume":"31","author":"Papadimitriou","year":"2017","journal-title":"Cancer Cell"},{"key":"B205","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-23-3333","article-title":"T-cell characteristics impact response and resistance to T-cell-redirecting bispecific antibodies in multiple myeloma","volume":"30","author":"Verkleij","year":"2024","journal-title":"Clin Cancer Res"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159353","article-title":"ISB 2001, a first-in-class trispecific BCMA and CD38 T cell engager designed to overcome mechanisms of escape from treatments for multiple myeloma by targeting two antigens","volume":"140","author":"Pihlgren","year":"2022","journal-title":"Blood"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023011225","article-title":"CD8 effector T cells enhance teclistamab response in BCMA-exposed and -naive multiple myeloma","volume":"8","author":"Firestone","year":"2024","journal-title":"Blood Adv"},{"key":"B208","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-137650","article-title":"Cite-Seq profiling of T cells in multiple myeloma patients undergoing BCMA targeting CAR-T or Bites immunotherapy","volume":"136","author":"Leblay","year":"2020","journal-title":"Blood"},{"key":"B209","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283758","article-title":"Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy","volume":"109","author":"Casey","year":"2024","journal-title":"Hematologica"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008118","article-title":"Invariant NKT cells dictate antitumor immunity elicited by a bispecific antibody cotargeting CD3 and BCMA","volume":"6","author":"Casey","year":"2022","journal-title":"Blood Adv"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-164717","article-title":"Dysfunctional hyper-expanded clonotypes and lack of TCR clonal replacement predict resistance to T cell engagers in multiple myeloma","volume":"140","author":"Neri","year":"2022","journal-title":"Blood"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136980","article-title":"Early pharmacodynamic changes in T-cell activation, proliferation, and cytokine production confirm the mode of action of BFCR4350A, a FcRH5\/CD3 T-cell-engaging bispecific antibody, in patients with relapsed\/refractory multiple myeloma","volume":"136","author":"Nakamura","year":"2020","journal-title":"Blood"},{"key":"B213","doi-asserted-by":"publisher","first-page":"10976","DOI":"10.1038\/s41598-022-14726-5","article-title":"Quantitative systems pharmacology modeling sheds light into the dose response relationship of a trispecific T cell engager in multiple myeloma","volume":"12","author":"Abrams","year":"2022","journal-title":"Sci Rep"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.3390\/cells13100879","article-title":"Pre-clinical assessment of SAR442257, a CD38\/CD3xCD28 trispecific T cell engager in treatment of relapsed\/refractory multiple myeloma","volume":"13","author":"Grab","year":"2024","journal-title":"Cells"},{"key":"B215","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"Wu","year":"2020","journal-title":"Nat Cancer"},{"key":"B216","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1038\/s41408-020-0331-4","article-title":"Blockade of VLA4 sensitizes leukemic and myeloma tumor cells to CD3 redirection in the bone marrow microenvironment","volume":"10","author":"Nair-Gupta","year":"2020","journal-title":"Blood Cancer J"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1097\/01.hs9.0000846460.44039.3d","article-title":"P897: Updated results from the ongoing phase 1 study of elranatamab, a Bcma targeted T-cell redirecting immunotherapy, for patients with relapsed or refractory multiple myeloma","volume":"6","author":"Dalovisio","year":"2022","journal-title":"HemaSphere"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-159711","article-title":"Teclistamab in combination with subcutaneous daratumumab and lenalidomide in patients with multiple myeloma: results from one cohort of MajesTEC-2, a phase1b, multicohort study","volume":"140","author":"Searle","year":"2022","journal-title":"Blood"},{"key":"B219","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-204929","article-title":"Combined PD-1 and Tim-3 blockade improves the anti-myeloma activity of T cells of patients on talquetamab","volume":"144","author":"Mouhieddine","year":"2024","journal-title":"Blood"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1016\/j.prp.2020.153114","article-title":"Immune checkpoint inhibitors in multiple myeloma: a review of the literature","volume":"216","author":"Caserta","year":"2020","journal-title":"Pathol Res Pract"},{"key":"B221","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1186\/s40164-023-00456-5","article-title":"Immune checkpoint inhibitors for multiple myeloma immunotherapy","volume":"12","author":"Liu","year":"2023","journal-title":"Exp Hematol Oncol"},{"key":"B222","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116095","article-title":"The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers","volume":"171","author":"Mestiri","year":"2024","journal-title":"BioMed Pharmacother"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.20892\/j.issn.2095-3941.2024.0055","article-title":"Immune checkpoint inhibitors: breakthroughs in cancer treatment","volume":"21","author":"Kong","year":"2024","journal-title":"Cancer Biol Med"},{"key":"B224","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-020-0337-2","article-title":"The future of cancer immunotherapy: microenvironment-targeting combinations","volume":"30","author":"Murciano-Goroff","year":"2020","journal-title":"Cell Res"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2021.1972802","article-title":"Advances in viral oncolytics for treatment of multiple myeloma - a focused review","volume":"14","author":"Sarwar","year":"2021","journal-title":"Expert Rev Hematol"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22052259","article-title":"Oncolytic virotherapy and microenvironment in multiple myeloma","volume":"22","author":"Marchica","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.1182\/blood.v124.21.4778.4778","article-title":"Combination therapy with reovirus and immunomodulatory drugs induces direct oncolytic and immune-mediated killing of multiple myeloma cells and overcomes stromal-mediated microenvironmental protection","volume":"124","author":"Parrish","year":"2014","journal-title":"Blood"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2017.272","article-title":"Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy","volume":"32","author":"Kelly","year":"2018","journal-title":"Leukemia"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1199173","article-title":"T cells, NK cells, and tumor-associated macrophages in cancer immunotherapy and the current state of the art of drug delivery systems","volume":"14","author":"Yang","year":"2023","journal-title":"Front Immunol"},{"key":"B230","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1146\/annurev-immunol-101921-044122","article-title":"Designing cancer immunotherapies that engage T cells and NK cells","volume":"41","author":"Kyrysyuk","year":"2023","journal-title":"Annu Rev Immunol"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2024.04.011","article-title":"Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy","volume":"42","author":"van Elsas","year":"2024","journal-title":"Cancer Cell"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15010251","article-title":"Combination of expanded allogeneic NK cells and T cell-based immunotherapy exert enhanced antitumor effects","volume":"15","author":"Wang","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B233","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.semcancer.2023.06.005","article-title":"Accelerating antibody discovery and design with artificial intelligence: recent advances and prospects","volume":"95","author":"Bai","year":"2023","journal-title":"Semin Cancer Biol"},{"key":"B234","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12929-025-01141-x","article-title":"Accelerating antibody discovery and optimization with high-throughput experimentation and machine learning","volume":"32","author":"Matsunaga","year":"2025","journal-title":"J BioMed Sci"},{"key":"B235","doi-asserted-by":"publisher","DOI":"10.1016\/j.tips.2022.12.005","article-title":"Computational and artificial intelligence-based methods for antibody development","volume":"44","author":"Kim","year":"2023","journal-title":"Trends Pharmacol Sci"},{"key":"B236","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1101\/2024.05.22.595383","article-title":"Timing antigenic escape in multiple myeloma treated with T-cell redirecting immunotherapies","volume":"144","author":"Papadimitriou","year":"2024","journal-title":"bioRxiv"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1822508\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T08:14:25Z","timestamp":1783412065000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1822508\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":236,"alternative-id":["10.3389\/fimmu.2026.1822508"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1822508","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"article-number":"1822508"}}